Radiopharm Theranostics (ASX:RAD) has received FDA Orphan Drug Designation for its Ga68-Trivehexin radiopharmaceutical technology, designed for imaging patients with pancreatic ductal adenocarcinoma.
The radiopharmaceutical product developer says the designation provides benefits such as tax credits, exemption from user fees, and potential market exclusivity.
Radiopharm Theranostics says potential follow-on indications include non-small cell lung cancer, head and neck, and colorectal cancer.
It plans to begin a Phase I clinical trial for the drug in the coming weeks.